Crotedumab
- Product Name
- Crotedumab
- CAS No.
- 1452387-69-7
- Chemical Name
- Crotedumab
- Synonyms
- REGN1193;Crotedumab;Crotedumab (anti-GCGR);Research Grade Crotedumab;Research Grade Crotedumab(DHE51802)
- CBNumber
- CB28080972
- Formula Weight
- 0
- MOL File
- Mol file
Crotedumab Property
- form
- Liquid
- color
- Colorless to light yellow
N-Bromosuccinimide Price
- Product number
- HY-P99357
- Product name
- Crotedumab
- Purity
- 99.22%
- Packaging
- 1mg
- Price
- $285
- Updated
- 2026/05/26
- Product number
- HY-P99357
- Product name
- Crotedumab
- Purity
- 99.22%
- Packaging
- 5mg
- Price
- $741
- Updated
- 2026/05/26
- Product number
- HY-P99357
- Product name
- Crotedumab
- Purity
- 99.22%
- Packaging
- 10mg
- Price
- $1188
- Updated
- 2026/05/26
- Product number
- A133
- Product name
- Crotedumab Biosimilar（Anti-GCGR Reference Antibody）
- Purity
- >98%
- Packaging
- 1mg
- Price
- $450
- Updated
- 2026/05/24
- Product number
- A133
- Product name
- Crotedumab Biosimilar（Anti-GCGR Reference Antibody）
- Purity
- >98%
- Packaging
- 5mg
- Price
- $750
- Updated
- 2026/05/24
Crotedumab Chemical Properties,Usage,Production
Uses
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes[1][2].
in vivo
Crotedumab (3-30 mg/kg; s.c. once weekly for 4 weeks) reduces blood glucose and body weight and induces reversible hyperglucagonemia and α-cell hyperplasia in DIO C57BL/6 mice[2].
Crotedumab (10 mg/kg; a single s.c.) markedly decreases blood glucose for 18 days in diabetic ob/ob mice[2].
REGN1193 (20 mg/kg; a single i.v.) produces a robust reduction in overnight-fasted blood glucose in both the conscious and anesthetized state of diabetic cynomolgus monkeys as well as in blood glucose measured 1 hour after feeding[2].
| Animal Model: | Diet-induced obese (DIO) male C57BL/6NTac mice were maintained on high-fat diet[2] |
| Dosage: | 3, 10, 30 mg/kg |
| Administration: | S.c. injection once weekly for 4 weeks |
| Result: | Markedly reduced blood glucose throughout the dosing period. Reversibly decreased body weight during the dosing period. Dose- and time-dependently increased glucagon and GLP-1. Reversibly increased α-cell area. |
References
[1] Kostic A, et, al. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018 Feb;20(2):283-291. DOI:10.1111/dom.13075
[2] Okamot H, et, al. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys. Endocrinology. 2015 Aug;156(8):2781-94. DOI:10.1210/en.2015-1011
Crotedumab Preparation Products And Raw materials
Raw materials
Preparation Products
Crotedumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 89686
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 7999
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310 15002144251
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24955
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9865
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 7081
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11972
- Advantage
- 58
- Tel
- 027-027-16602739303 16602739303
- 673003916@qq.com
- Country
- China
- ProdList
- 4565
- Advantage
- 58
- Tel
- 17721492509 17721492509
- 460170712@qq.com
- Country
- China
- ProdList
- 4926
- Advantage
- 58